Clinical Trial Update: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing the synergistic effect of elemene plus TKIs versus TKIs alone in EGFR-mutated advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Elemene (elemene)
• Tyrosine kinase inhibitors (TKIs) (tyrosine kinase inhibitors)

Snippet

Sponsor: Tian Xie | Conditions: Carcinoma, Non-Small-Cell Lung Cancer | Phase 4 | Status: UNKNOWN